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Despite the prevalence and known adverse impacts of depression after hematopoietic cell transplantation
(HCT), little is known about the trajectory of depression occurring after HCT, or which pretransplantation risk
factors might help predict new or worsening post-HCT depression. This secondary analysis evaluated the
relationships between pre-HCT patient-reported outcomes and demographic characteristics and post-HCT
depression. A total of 228 adult HCT patients were evaluated pre-HCT (T1) and again at 6 to 7 weeks post-
HCT (T2), using touch-screen computers in the transplantation clinic during participation in a larger trial.
Measures evaluated included the Symptom Distress Scale, the EORTC QLQ-C30 for quality of life, a single-item
pain intensity question, and the Patient Health Questionnaire 9 for measurement of depression. At T1, rates of
depression were quite low, with only 6% of participants reporting moderate or higher depression. At T2,
however, the prevalence of moderate or higher depression was 31%. We observed a strong linear relationship
in PHQ-9 scores between T1 and T2 (P < .0001). Depression score at T1 was a signiﬁcant predictor of
depression score at T2 (P ¼ .03), as was poorer emotional function at T1 (P < .01). Our results indicate that
post-HCT depression is common, even in patients with a low pre-HCT depression score. Frequent screening
for symptoms of depression at critical time points, including 6 to 7 weeks post-HCT, are needed in this
population, followed by referrals to supportive care as appropriate.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Success rates for hematopoietic cell transplantation (HCT)
have continued to improve as the procedure has been
increasingly reﬁned [1,2]. Despite this signiﬁcant progress,
HCT remains an extraordinarily stressful procedure physi-
cally, mentally, and emotionally [3,4]. One signiﬁcant, and
potentially limiting, symptom associated with HCT is
depression. Depression is one of the most common psychi-
atric conditions occurring during and after cancer treatment.
The estimated prevalence of depression across cancer
patients ranges from 3% to >50%, depending on the timing
andmethod used to measure the symptoms [5]. Studies have
indicated that depression is prevalent in patients undergoing
HCT, with an estimated one-quarter to one-third of HCT
recipients experiencing depression during the ﬁrst 100
days post-transplantation or during recovery from trans-
plantation [3,6-9].
Depression has many potential negative psychosocial and
physical consequences in HCT recipients. It can interfereedgments on page 949.
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14.03.010signiﬁcantly with quality of life; physical, social, and recre-
ational activities; and overall health, and can be comorbid
with other signiﬁcant concerns, such as post-traumatic stress
disorder and suicidal ideation in HCT survivors [3,10,11].
Depression also can interfere with cancer treatment adher-
ence and is associated with negative health behaviors, such
as tobacco and alcohol use [12,13]. Depression is well known
to be associated with increased mortality in the general
population [14-16], as well as in cancer patients [17].
Depression may be an independent risk factor for survival
after HCT over and above its status as a potential indicator of
poorer health status [7,18].
National accreditation bodies, including the National
Comprehensive Cancer Network [19] and the Commission on
Cancer [20], have mandated that distress screening be
completed during treatment. For patients with clinical evi-
dence of moderate or severe distress, the oncology team
must “assess the psychological, behavioral, and social prob-
lems.that may interfere with their ability to participate
fully in their health care and manage their illness and its
consequences” [20]. Patients must then be referred for
appropriate supportive care and creation of a follow-up plan.
Thus, for HCT clinicians, early identiﬁcation of depression is a
critical element of comprehensive HCT care, along with
appropriate referrals and interventions to address symp-
toms. Understanding the risk factors and clinical course ofTransplantation.
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and at what time points screening should occur [11].
The time course of depressive symptoms may vary
signiﬁcantly among HCT recipients. In some, depression may
occur before HCT and persist (or even worsen) throughout
the course of treatment, whereas in others, depression may
not appear until weeks or months after HCT, remaining
a long-term concern for patients undergoing HCT. In one
study of HCT survivors at 1 to 3 years post-transplantation,
15% reported moderate to severe depressive symptoms,
with recipients of allogeneic HCT (versus recipients of
autologous HCT) and those with poorer functional status
reporting higher levels of depression [10]. Another long-term
study of recovery post-HCT found that 19% of patients
continued to experience depressive symptoms at 5 years
post-HCT [6].
Despite the prevalence and known adverse impacts of
depression after HCT, little is known about the trajectory of
depression immediately after HCT, orwhich pretransplantation
risk factors might help predict new or worsening depression
post-HCT. We conducted the present analysis to evaluate the
relationships betweenpre-HCT patient-reported outcomes and
demographic characteristics and post-HCT depression. Vari-
ables of interest included symptom distress, quality of life,
demographic data, and social roles (eg, vocational status,
relationship status). The purpose of the analysis is to aid cli-
nicians in identifying patients who might be at high risk for
depression in the early post-HCT period, facilitating early
detection and thus more effective intervention for those
patients.
PATIENTS AND METHODS
Sample
Research participants in the larger Electronic Self-Report Asses-
smenteCancer (ESRA-C) study [21], from which these data were
collected, were recruited from the Seattle Cancer Care Alliance (SCCA), a
consortium of the University of Washington Medical Center, Fred
Hutchinson Cancer Research Center, and Seattle Children’s Hospital. The
SCCA cared for 3609 new patients in 2006, when these data were
collected, the majority of whom (85%) were from Washington state.
Eligibility criteria for the analytic sample included the following: new
patients being evaluated for HCT, at least 18 years of age, able to
communicate in English, and able to understand the study information
and provide informed consent. Participants were included irrespective of
the presence of diagnosis or treatment of psychiatric conditions, as long
as they met the criteria for HCT. Between April 2005 and November 2006,
a total of 228 eligible HCT patients were enrolled in the study.
Procedures
The methods and procedures of the ESRA-C study have been described
in detail elsewhere [21]. In brief, baseline assessments (T1) were adminis-
tered via touch-screen computer at a clinic visit before the start of HCT
conditioning. At the ﬁrst ambulatory visit post-HCT (at 6 to 7 weeks),
patients were surveyed a second time (T2) using the samemethodology. The
technical aspects and navigability of the ESRA-C program have been
described previously [22-24]. The ESRA-C has beenwell received by patients
[21,25]. During the T1 session, patients were presented with an introductory
screen, followed by demographic questions. They were then presented with
4 validated questionnaires during both the T1 and T2 survey sessions:
 SymptomDistress Scale (SDS) [26]. The 13-item SDS assesses the level
of symptom distress for 11 symptoms, including nausea, appetite,
insomnia, pain, fatigue, concentration, and others. Each item is scored
on a scale of 1 to 5 with descriptive options. The SDS score is the sum
of all item scores.
 The European Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ)-C30, version 3 [27].
The EORTC QLQ-C30 is a questionnaire developed to assess the quality
of life of cancer patients, including those undergoing HCT [28].
The QLQ-C30 incorporates 9 multi-item scales, including 5 functional
scales (physical, role, cognitive, emotional and social), 3 symptom
scales (fatigue, pain, nausea and vomiting), and a global health andquality of life scale. Each subscale is a multi-item index that yields a
score of 0 to 100, with higher scores indicating better function for the
functional scales (eg, emotional function) andmore symptoms for the
symptom scales (eg, fatigue). Emotional function questions cover
such symptoms as irritability, worry, tension, and depression.
 A single-item numerical pain intensity scale of 0 to 10, with
0 indicating no pain and 10 indicating the worst pain imaginable.
 The 9-item Patient Health Questionnaire (PHQ-9) depression scale
[29]. The PHQ-9 has been validated for in-person self-report or
interviewer administration, as well as for administration over the
telephone [30-33]. Standard PHQ-9 depression scores were cate-
gorized as follows: none (4), mild (5 to 9), moderate (10 to 14),
moderately severe (15 to 19), and severe (20). A score of 10 has
been identiﬁed as the optimal cutoff for identifying probable major
depressive disorder (sensitivity, 0.88; speciﬁcity, 0.88) in primary
care patients [29]. For analysis, we classiﬁed patients into 2 groups,
“no/mild” depression (PHQ-9 total score <10) and “moderate or
higher” depression (PHQ-9 total score 10). To minimize patient
burden, we used the presence of at least 1 cardinal symptom of
depression on at least half of the days in the previous 2 weeks,
either anhedonia or depressed mood, as a trigger for completing
the remaining 7 items of the PHQ-9. Initial screening in this
manner, known as the PHQ-2, has been validated in medical pop-
ulations [34-36]. Participants who did not trigger the full PHQ-9
were classiﬁed as having “no/mild” depression. To provide addi-
tional data for distressed subjects, the full PHQ-9 was also triggered
in the case of speciﬁc responses on the QLQ-C30 (score of 50 on a
possible 100 for the Emotional Function or Cognitive Function
subscale) or SDS (score of 3 on the response range of 1 to 5 for the
fear/worry, concentration, or sleep disturbance items).Analysis
Baseline patient socioeconomic factors and quality of life measures
were compared between dropouts and those completing the study using
the t-test for continuous variables (age) or the Fisher exact/chi-square test
for categorical variables. A generalized McNemar test was used to check for
potential pattern changes in depression between T1 and T2. Logistic
regressionwas used to predict moderate or higher depression at T2, with a
list of preselected baseline variables, including minority (or not), income,
education, working status, computer use, partnered (or not), transplant
type, and baseline measures on the QLQ-C30, SDS, pain intensity scale, and
the PHQ-9. The factors were ﬁrst checked individually, adjusting for T1
depression status, and then factors with a P value <.20 were included in
the multivariable model. Backward model selection was used for variable
selection, and all variables with a P value <.10 were retained in the ﬁnal
model. Odds ratios and 2-sided P values were calculated. Analyses were
performed with SAS version 9.2 (SAS Institute, Cary, NC) and R version
2.15.0 (R Institute for Statistical Computing, Vienna, Austria).
RESULTS
A total of 228 HCT recipients were enrolled in the study.
Thirty-six of the participants did not complete the assess-
ment at both time points, with attrition due mainly to death
or illness; thus, the ﬁnal analytic sample comprised 192
participants. There were no signiﬁcant differences in de-
mographic characteristics between study completers and
noncompleters, although there were trends toward older age
(P ¼ .06) and lower likelihood of working at T1 (P ¼ .07) in
noncompleters compared with completers. However, non-
completers did have signiﬁcantly lower global quality of life
scores (subscale of the QLQ-C30) at T1 compared with
completers (P ¼ .04).
Demographic and clinical characteristics of the 192
study participants are shown in Table 1. The sample was
59% male, and the majority were married, had 2 or more
years of college education, and used computers at home
and/or work. Participants were predominately Caucasian
and non-Hispanic/Latino (91%). The majority of partici-
pants (59%) were working, on medical leave, or in school.
Changes in PHQ-9 depression categories from T1 to T2 are
presented in Table 2. At T1, rates of depressionwere low, with
only 11 participants (6%) reporting moderate or higher
Table 3
Univariate Logistic Regression Predicting Moderate or Higher Depression
(PHQ-9 Score 10) at T2, Adjusting for Depression Status at Baseline
T1 Predictor b Odds Ratio P Value
Male sex 0.12 0.89 .73
Minority race/ethnicity* 0.97 0.38 .18
Working at T1y 0.54 1.72 .12
College education or more 0.58 1.78 .18
Married or partnered 0.53 1.69 .19
Annual income $55,000 0.17 1.18 .63
Computer userz 0.01 1.01 .98
Global quality of life, EORTC QLQ-C30 0.01 0.99 .15
Physical function, EORTC QLQ-C30 0.01 0.99 .43
Role function, EORTC QLQ-C30) 0 1 .56
Emotional function, EORTC QLQ-C30 0.04 0.96 <.01
Cognitive function, EORTC QLQ-C30 0 1 .66
Social function, EORTC QLQ-C30 0 1 .45
Fatigue, SDS 0.01 1.01 .15
Nausea/vomiting, SDS 0 1 .96
Pain, SDS 0 1 .94
Total symptom distress, SDS 0.08 1.08 .02
Allogenieic transplant 0.33 1.39 .33
Impact on sexual activities and interest 0.11 1.12 .32
Fever/chills 0.06 0.94 .89
PHQ-9 indicates 9-item Patient Health Questionnaire; T1, pre-HCT; EORTC
European Organization for Research and Treatment of Cancer; SDS, Symp-
ton Distress Scale.
Depression status at T1 is signiﬁcantly associated with that at T2 (P< .0001).
Signiﬁcant predictors are in bold type.
* Deﬁned as non-Caucasian race and/or Hispanic/Latino ethnicity, by
self-report.
y Deﬁned as working full-time, part-time, on full or partial medical leave,
or student. “Not working” is deﬁned as being unemployed or retired at T1.
z Uses a computer at least sometimes at home or work.
Table 1
Baseline Demographic Data and Clinical Characteristics (n ¼ 192)
Variable Value
Age, yr, median (range) 51 (19-75)
Male sex, n (%) 114 (59)
Minority race/ethnicity, n (%)* 17 (9)
Married or partnered, n (%) 139 (72)
College education or more, n (%) 147 (77)
Annual income $55,000, n (%) 103 (54)
Working at T1, n (%)y 114 (59)
Computer user, n (%)z 177 (92)
Cancer diagnosis, n (%)
Leukemias 92 (48)
Lymphomas 59 (31)
Myelomas 38 (20)
Other 3 (2)
Transplant type, n (%)
Autologous 76 (40)
Allogeneic 116 (60)
* Deﬁned as non-Caucasian race and/or Hispanic/Latino ethnicity, by
self-report.
y Deﬁned as working full-time, part-time, on full or partial medical leave,
or student. “Not working” is deﬁned as being unemployed or fully retired.
z Uses a computer sometimes or often at home or work.
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ever. This difference in the percentage of participants expe-
riencing moderate or higher depression between T2 and T1
was signiﬁcant (P < .001, generalized McNemar test).
We found a strong linear relationship in PHQ-9 category
scores between T1 and T2 (P < .0001). Results of univariate
analyses are shown in Table 3. Adjusting for T1 depression
status, depression at T2 was associated with poorer
emotional function (P < .01) and greater symptom distress
(P ¼ .02) at T1. Transplant type (autologous versus alloge-
neic) was not a signiﬁcant predictor of elevated depression
at T2. The prevalence of moderate or higher depression was
7% (8 of 116) at T1 and 34% (40 of 116) at T2 in the allo-
geneic HCT recipients, and 4% (3 of 76) at T1 and 26% (20 of
76) at T2 in the autologous HCT recipients. These differ-
ences were not statistically signiﬁcant (P ¼ .53 at T1, P ¼ .27
at T2).
The results of multivariate analyses are shown in Table 4.
In multivariate analysis, T1 depression score remained a
signiﬁcant predictor of depression scores at T2 (P ¼ .03), as
did poorer emotional function at T1 (P < .01); however,
elevated symptom distress was no longer signiﬁcant (P ¼.18)
in predicting elevated depression at T2. T1 working status
trended toward signiﬁcance (P ¼ .07), such that those who
were working at T1 (even if on medical leave during their
treatment) had higher rates of depression at T2. All possible
2-way interactions in the multivariate model were tested,
and none were found to be signiﬁcant.Table 2
Change in PHQ-9 Depression Scores from T1 to T2
T2 Total
No/mild Moderate or higher
T1
No/mild 131 (68.2%) 50 (26.1%) 181 (94.3%)
Moderate or higher 1 (0.5%) 10 (5.2%) 11 (5.7%)
Total 132 (68.7%) 60 (31.3%) 192 (100%)
PHQ-9 indicates 9-item Patient Health Questionnaire; T1, pre-HCT.
The number of participants (with percentage of total number) meeting
criteria for no/mild and moderate or higher depression categories, based on
PHQ-9 scores, is listed at each time point. Categories: no/mild depression,
PHQ-9 score <10; moderate or higher depression, PHQ-9 score 10.DISCUSSION
This exploratory investigation adds to the growing body
of literature indicating that depression is common after HCT,
and provides information to help identify patients at risk for
post-HCT depression. Although few patients (6%) met the
criteria for moderate or higher depression before HCT, nearly
one-third (31%) met the criteria for moderate or higher
depression when assessed at 6 to 7 weeks post-HCT. Many
participants who had elevated depression scores at T2 were
not depressed at T1, indicating that even if a patient seems to
be doing well emotionally before HCT, he or she may be at
signiﬁcant risk for post-HCT depression.
At our center, as at many others, all HCT recipients receive
a comprehensive social work evaluation before undergoing
transplantation. Several factors put patients at elevated risk
for post-HCT depression, and these factors should help cli-
nicians identify patients whomerit closer monitoring as they
proceed through the transplantation process. Not surpris-
ingly, depression scores at T1 were strongly associated withTable 4
Multivariate Logistic Regression Predicting Moderate or Higher Depression
(PHQ-9 Score 10) at T2, Adjusting for Depression Status at Baseline
T1 Predictor b Odds Ratio P Value
Moderate or higher depression
(PHQ-9 score ‡10)
2.44 11.49 .03
Working at T1* 0.65 1.92 .07
Emotional function, EORTC QLQ-C30 0.034 0.96 <.01
PHQ-9 indicates 9-item Patient Health Questionnaire; T1, pre-HCT;
EORTC, European Organization for Research and Treatment of Cancer.
Bold text indicates signiﬁcant predictors; predictors trending toward
signiﬁcance are in italics.
* Deﬁned as working full-time, working part-time, on full or partial
medical leave, or student. “Not working” is deﬁned as being unemployed or
fully retired at T1.
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symptoms of depression should be monitored closely for
worsening symptoms post-HCT. Another risk factor for
elevated depression at T2 was lower self-reported emotional
function, a subscale of the EORTC QLQ-C30, at T1. This effect
was signiﬁcant even after controlling for depression scores at
T1, indicating the need for clinicians to attend not only to
symptoms of depression per se, but also to other broad
indicators of emotional distress before HCT, such as anxiety,
tension, and irritability. Others also have identiﬁed pre-
transplantation distress (usually deﬁned as anxiety or
depression) as the strongest predictor of post-HCT anxiety or
depression [6,37].
The overall pretransplantation symptom burden was
another predictor of post-transplantation difﬁculties with
depression. Elevated SDS scores were predictive of high
depression post-HCT in our univariate analysis (controlling
for baseline depression), underscoring the importance of
helping patients cope with their myriad symptoms before
undergoing HCT and of rescreening patients with high
baseline symptom burden for depression at 1 to 2 months
post-HCT. The impact of symptom distress at T1 was not
signiﬁcant when analyzed in a multivariate model, however,
possibly indicating that emotional distress (whichmay result
in part from symptom burden) is a stronger factor predicting
future depression.
An interesting, albeit nonsigniﬁcant, trend noted was
that participants with a vocational status that implied
continuing responsibility for this role (including those who
were working full time or part time, on full- or part-time
leave, or in school) at T1 had higher depression at T2. One
potential explanation for this trend is that being employed
or in school carries with it a set of expectations and stress
that continues into HCT, even if the patient is on leave. It is
possible that the added stress of these vocational demands
contributes to depression after HCT. Indeed, a recent study of
a non-HCT cancer sample found that work-related stress is
common during cancer treatment, even in patients on
medical leave [38]. Patients who are working or in school in
some capacity during the HCT process may require addi-
tional support and strategies for managing vocational de-
mands and stress in the context of diminished medical and
psychosocial reserves. This issuemerits exploration in future
studies.
Strengths of this study include the use of reliable and
validated self-reporting instruments at 2 time points in a
well-established HCT program. Thus, we were able to iden-
tify several pretransplantation predictors associated with
depression at T2. Nonetheless, the relative weakness of the
associations that we found suggests that other predisposing
and precipitating factors may contribute to depression post-
HCT. The time course of depression symptoms from T1 to T2
likely reﬂects the uniqueness of HCT compared with other
cancer treatments. Given the eligibility criteria for trans-
plantation, it is possible that HCT recipients report that they
are more optimistic and hopeful at baseline (ie, before
transplantation) than other patients starting cancer treat-
ment, who are often extremely distressed after receiving
their diagnosis and before starting their initial treatments
[8]. In addition, our T2 assessment was done at 6 to 7 weeks
post-HCT, the time when most patients are discharged from
the hospital and have had several weeks to recover from
deconditioning and other lingering acute symptoms, thereby
minimizing the direct effects of acute hospitalization on
depressive symptoms. In many cases, however, adversephysical symptoms are still present at 6 to 7 weeks post-HCT,
and these symptoms might have affected self-reports of
mood. Future studies should examine the course and longi-
tudinal predictors of depression at additional post-HCT time
points. In our analysis, transplant type (allogeneic versus
autologous) was not predictive of post-HCT depression, but
this variable warrants more thorough evaluation in future
studies, given that these 2 groups of HCT recipients can have
signiﬁcantly different post-transplantation medical courses.
An additional strength of this study is the electronic
collection of data via touch-screen computers. The majority
of our participants were familiar with computers. Previous
studies have shown that measurement of depression and
symptom distress with touch screen computers is feasible
and reliable [8]. Moreover, computer-administered symptom
screens are clinically useful, readily providing real-time
scores and symptom information to clinicians, who can
then discuss it with patients in a timely manner [21]. Our
data were collected only via computer, however, and our
ﬁndings should be replicated in populations less well-
acquainted with this modality.
The participants in this study were relatively well-
educated and afﬂuent, and predominantly Caucasian and
non-Hispanic/Latino. It is possible that samples of more
diverse groups might have differing rates of, and risk factors
for, post-HCT depression. Future studies should address
these concerns. Finally, there are broad knowledge gaps in
terms of the effectiveness of brief interventions to address
depression and enhance coping that can be implemented in
the HCT setting.
Organizations such as the American College of Surgeons
Commission on Cancer [20] mandate screening for distress
(including depression, anxiety, and other psychosocial difﬁ-
culties) at least once for all patients treated at participating
cancer centers. However, our ﬁndings suggest that screening
for distress just once pretransplantation may be insufﬁcient,
and that 6 to 7 weeks post-HCT may be an important
assessment point. This study and others have demonstrated
that depression screening is feasible and accepted by both
patients and medical providers in a busy HCT clinic setting
[8,11]. Our ﬁndings underscore the importance of assessing
emotional distress in HCT clinics at multiple time points
during the course of treatment. Periodic depression
screening at pivotal points along the trajectory of treatment
and recovery provides opportunities for earlier referral and
intervention for those patients who are either already
experiencing depressive symptoms or at risk for developing
depression. Proactive efforts to manage depression in HCT
recipients may improve their overall recovery and post-
transplantation quality of life.ACKNOWLEDGMENTS
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